Fig. 1 · Structure

Documents & Downloads

Sinomenine hydrochloride

Cat. No. A12221 CAS 6080-33-7
Sinomenine hydrochloride enhancement of the inhibitory effects of anti-transferrin receptor antibody-dependent on the COX-2 pathway in human hepatoma cells.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Sinomenine hydrochloride Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Sinomenine hydrochloride from 3 published references. In vitro models include rat microglia (RM) cells; BV2 cells.

Sinomenine hydrochloride In Vitro Studies

In rat microglia cells, combined LPS and Sinomenine treatment yielded 20 differentially expressed miRNAs compared with LPS alone, including 11 upregulated and 9 downregulated miRNAs. In BV2 cells, Sinomenine pretreatment did not affect the ADDL-induced increase in IL-12 compared with ADDL alone. In B16-F10 cells, Sinomenine decreased viability in a dose-dependent manner. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Sinomenine and LPS treatment in rat microglia

Cell-based study · Rat microglia (RM) cells [1]

Rat microglia cells treated with both LPS and Sinomenine were compared with cells treated with LPS alone. Sequencing identified 20 differentially expressed miRNAs, with 11 upregulated and 9 downregulated.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
miRNA sequencing analysisdifferentially expressed exosomal miRNAs 20 differentially expressed miRNAs; 11 upregulated and 9 downregulated miRNAs[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.5 µM
Exposure duration
1 µg/mL LPS for 4 h; with or without SINO for 24 h
Method
Subsequently, the cells were treated with or without SINO
Co-treatment
Other interventions in this design: LPS 1 µg/mL. Compound effect isolated by the comparison: RM cells treated with LPS alone (LPS-RM-Exos); RM cells treated with both LPS and SINO (SINO-RM-Exos).
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Sinomenine

The paper names Sinomenine without stating the salt or form; not verified as the hydrochloride form supplied as A12221. No dose conversion or lot validation.

Materials and methods > Microglial cell culture and treatments (S48); Materials and methods > Isolation and identification of RM exosomes (RM-Exos) (S77, S78); Materials and methods > miRNA microarray analysis (S90); Results > SINO suppresses the LPS-induced inflammatory response in RM cells and enhances their M2 polarization (S163); Results > Exosomal mir-223-3p mediates the protective effects of SINO-activated microglia on neuronal pyroptosis (S192, S193, S197); Fig. 1 legend (S209)

miRNA sequencing analysis: miRNA sequencing analysis; comparator: RM cells treated with LPS alone (LPS-RM-Exos) — Results > SINO suppresses the LPS-induced inflammatory response in RM cells and enhances their M2 polarization (S163); Results > Exosomal mir-223-3p mediates the protective effects of SINO-activated microglia on neuronal pyroptosis (S192, S193, S197)

Sinomenine pretreatment in ADDL-exposed microglial cells

Cell-based study · BV2 cells [2]

BV2 cells received Sinomenine before ADDL exposure. Compared with ADDL alone, Sinomenine pretreatment did not affect the ADDL-induced increase in IL-12.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
levels of IL-6, IL-10, IL-12, TNF-α, IFN-γ and MCP-1Reported result 10-4 M sinomenine; BV2 cells were treated with sinomenine for 1.5 h, then with ADDL for 12 h: Sinomenine did not affect ADDL-induced increase in level of IL-12 (fold control, ADDL = 1.39 ± 0.15; ADDL + sinomenine = 1.27 ± 0.11, p > 0.26 compared to ADDL; n = 7 in all groups).[2]

Literature-Reported Treatment Conditions

Treatment concentration
10-4 M
Exposure duration
sinomenine for 1.5 h, then with ADDL for 12 h
Method
treated with sinomenine before addition of ADDL
Vehicle
DMSO concentration was 0.1%
Co-treatment
Other interventions in this design: ADDL 2 μM. Compound effect isolated by the comparison: compared to ADDL.
Reported limits
Removed after verification: value.
Methods and source locations

Compound reported in the paper: Sinomenine

The paper names Sinomenine without stating the salt or form; not verified as the hydrochloride form supplied as A12221. No dose conversion or lot validation.

Methods > Preparation of oligomeric amyloid beta (S8); Methods > Cell culture and treatments (S9, S15); Methods > Cytokine bead array assay (S47); Results > Sinomenine inhibits amyloid-β-induced increase in level of reactive oxygen species in microglial cells (S67, S71, S72, S73, S77); Results > Sinomenine reduces A-beta-induced increases in inflammatory molecules (S89, S95)

levels of IL-6, IL-10, IL-12, TNF-α, IFN-γ and MCP-1: levels of IL-6, IL-10, IL-12, TNF-α, IFN-γ and MCP-1; comparator: ADDL — Methods > Cell culture and treatments (S15); Results > Sinomenine inhibits amyloid-β-induced increase in level of reactive oxygen species in microglial cells (S67, S71, S72); Results > Sinomenine reduces A-beta-induced increases in inflammatory molecules (S89, S95)

Sinomenine effects on melanoma cell viability

Cell-based study · B16-F10 cells [3]

B16-F10 cells were treated with Sinomenine, and viability was assessed using a CCK8 assay. Sinomenine decreased cell viability in a dose-dependent manner.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
cell viability was analyzed by CCK8 assayReported result 0–100 μM for 24 hours: SIN dose dependently decreased the viability of B16-F10 cells.[3]

Literature-Reported Treatment Conditions

Treatment concentration
0, 12.5, 25, 50, and 100 μM
Exposure duration
24 hours
Reported limits
Not stated in the sentences used: route, vehicle.
Methods and source locations

Compound reported in the paper: Sinomenine

The paper names Sinomenine without stating the salt or form; not verified as the hydrochloride form supplied as A12221. No dose conversion or lot validation.

Materials and methods > Cell viability assay (S11); Results > SIN inhibits proliferation and promotes apoptosis of B16-F10 cells (S40, S41); Figure 1 legend (S60, S61, S67)

cell viability was analyzed by CCK8 assay: cell viability was analyzed by CCK8 assay; comparator: untreated control — Results > SIN inhibits proliferation and promotes apoptosis of B16-F10 cells (S40, S41); Figure 1 legend (S61)

Sinomenine hydrochloride In Vivo Studies

Sinomenine was administered daily by subcutaneous injection to BALB/c mice bearing melanoma xenografts. Tumor volume and weight decreased remarkably compared with the untreated group. [3]

Sinomenine treatment in melanoma xenograft mice

Animal study · Six-week-old BALB/c mice; melanoma xenograft mouse model; n=6 [3]

BALB/c mice bearing melanoma xenografts received daily subcutaneous Sinomenine treatment. Tumor volume and weight decreased remarkably compared with the untreated group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Calculation of tumor volume at 5–35 days after injectionReported result daily treatment of SIN (100 mg/kg) for 35 days: the tumor volume and weight decreased remarkably with SIN treatment, compared with the results in the untreated group[3]

Conditions shared by the study groups

Route
subcutaneously
Treatment course
daily treatment of SIN (100 mg/kg) for 35 days
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Sinomenine 100 mg/kguntreated groupdaily treatment of SIN (100 mg/kg) for 35 days: the tumor volume and weight decreased remarkably with SIN treatment, compared with the results in the untreated group[3]
Sinomenine 100 mg/kg
Model: Six-week-old BALB/c mice; melanoma xenograft mouse model; n=6
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Sinomenine

The paper names Sinomenine without stating the salt or form; not verified as the hydrochloride form supplied as A12221. No dose conversion or lot validation.

Materials and methods > Animals and experimental protocols (S22, S26); Results > SIN relieves tumor growth of melanoma in vivo (S45, S46); Figure 2 legend (S68, S69, S72)

Calculation of tumor volume at 5–35 days after injection: Calculation of tumor volume at 5–35 days after injection; comparator: untreated group — Results > SIN relieves tumor growth of melanoma in vivo (S46); Figure 2 legend (S68, S69)

Sinomenine 100 mg/kg · Materials and methods > Animals and experimental protocols (S26); Results > SIN relieves tumor growth of melanoma in vivo (S46); Figure 2 legend (S68)

Specifications

Manufacturer Adooq Bioscience
CAS Number 6080-33-7
Formula C19H23NO4.HCl
Molecular Weight 365.85
SMILES
CN1CC[C@@]23CC(=O)C(=C[C@@H]2[C@@H]1CC4=C3C(=C(C=C4)OC)O)OC.Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 68 mg/mL (185.86 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Sinomenine hydrochloride Research References

  1. [1] Yang Q, Chen Q, Zhang KB, et al. Sinomenine alleviates neuroinflammation in chronic cerebral hypoperfusion by promoting M2 microglial polarization and inhibiting neuronal pyroptosis via exosomal miRNA-223-3p. Acta Neuropathol Commun (2025). PMID: 40045356 DOI: 10.1186/s40478-025-01950-z Source material
  2. [2] Shukla SM, Sharma SK. Sinomenine inhibits microglial activation by Aβ and confers neuroprotection. J Neuroinflammation (2011). PMID: 21917137 DOI: 10.1186/1742-2094-8-117 Source material
  3. [3] Sun Z, Zheng L, Liu X, et al. Sinomenine inhibits the growth of melanoma by enhancement of autophagy via PI3K/AKT/mTOR inhibition. Drug Des Devel Ther (2018). PMID: 30122899 DOI: 10.2147/DDDT.S155798 Source material

Added to your cart

View Cart Checkout
Loading...